Related Experiment Video
Updated: May 11, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Angiotensinogen promoter polymorphisms predict low diffusing capacity in U.S. and Spanish IPF cohorts
My-Trang T Dang1, Chenyang Gu, Jeannie I Klavanian
1Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, USA.
Lung
|May 30, 2013
Summary
Genetic variations in angiotensinogen (AGT) are linked to reduced lung function in idiopathic pulmonary fibrosis (IPF). Specific genotypes (CC at -20, AA at -6) and haplotypes (CA) are associated with worse pulmonary function tests in IPF patients, with gender-specific effects observed.
Area of Science:
- Genetics
- Pulmonology
- Fibrotic Diseases
Background:
- Single nucleotide polymorphisms (SNPs) in angiotensinogen (AGT) at -20 and -6 positions are linked to fibrotic disease severity.
- Previous research indicated an association between the A-6 allele and idiopathic pulmonary fibrosis (IPF) progression.
- This study investigated if specific AGT genotypes (homozygous CC at -20, AA at -6) worsen pulmonary function in IPF.
Purpose of the Study:
- To examine the association between AGT gene polymorphisms (-20A>C and -6G>A) and pulmonary function measures in IPF patients.
- To determine if specific genotypes and haplotypes of AGT confer worse pulmonary function outcomes in IPF.
- To explore the influence of gender on the relationship between AGT polymorphisms and lung function in IPF.
Main Methods:
- Utilized multiple logistic regression analysis on data from the NIH Lung Tissue Research Consortium (LTRC) and a Spanish cohort.
- Adjusted for relevant covariates to accurately assess the impact of AGT SNPs on pulmonary function.
- Analyzed the association of specific genotypes (CC at -20, AA at -6) and haplotypes (CA) with pulmonary function test results.
Main Results:
- The CC genotype at -20 was significantly associated with reduced diffusing capacity in males across both cohorts (p=0.0028 LTRC; p=0.017 Spanish).
- In females, the AA genotype at -6 correlated with lower forced vital capacity (FVC) (p=0.0082) and alveolar volume (Valv) (p=0.022).
- The CA haplotype at -20 and -6 in AGT was also strongly linked to diminished diffusing capacity in males in both study groups.
Conclusions:
- This research provides the first evidence linking AGT polymorphisms (-20A>C and -6G>A) to reduced pulmonary function in IPF.
- It is the first study to demonstrate a gender-specific effect of AGT polymorphisms on lung fibrosis.
- Findings suggest AGT gene variants are important genetic factors influencing pulmonary function in IPF, with implications for disease severity and progression.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...